Mark S. Shaefer

3.6k total citations
79 papers, 2.4k citations indexed

About

Mark S. Shaefer is a scholar working on Infectious Diseases, Virology and Pharmacology. According to data from OpenAlex, Mark S. Shaefer has authored 79 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Infectious Diseases, 38 papers in Virology and 14 papers in Pharmacology. Recurrent topics in Mark S. Shaefer's work include HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (33 papers). Mark S. Shaefer is often cited by papers focused on HIV/AIDS drug development and treatment (44 papers), HIV Research and Treatment (38 papers) and HIV/AIDS Research and Interventions (33 papers). Mark S. Shaefer collaborates with scholars based in United States, United Kingdom and Canada. Mark S. Shaefer's co-authors include Paul Wannamaker, Lisa Ross, Denise Sutherland‐Phillips, Qiming Liao, Edwin DeJesus, Benjamin Young, Cindy Vavro, Linda Yau, Philip Lackey and Joseph J. Eron and has published in prestigious journals such as The Lancet, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Mark S. Shaefer

79 papers receiving 2.3k citations

Peers

Countries citing papers authored by Mark S. Shaefer

Since Specialization

Citations

This map shows the geographic impact of Mark S. Shaefer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Shaefer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Shaefer more than expected).

Fields of papers citing papers by Mark S. Shaefer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Shaefer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Shaefer. The network helps show where Mark S. Shaefer may publish in the future.

Co-authorship network of co-authors of Mark S. Shaefer

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Shaefer. A scholar is included among the top collaborators of Mark S. Shaefer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Shaefer. Mark S. Shaefer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort 2021 ·AIDS Patient Care and STDs ·Karam Mounzer, Jennifer S Fusco, (unknown), Laurence Brunet, Vani Vannappagari, Kevin R. Frost, Mark S. Shaefer, Alex R. Rinehart, (unknown), Gregory Fusco	7
2	Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30–49 vs ≥50 mL/min 2019 ·PLoS ONE ·Lisa Ross, A. Sarah Walker, Yu Lou, Allan R. Tenorio, Diana M. Gibb, (unknown), Charles F. Gilks, Cynthia McCoig, Paula Munderi, Godfrey Musoro, Cissy Kityo, Heiner Grosskurth, James Hakim, Peter Mugyenyi, Amy Cutrell, (unknown), Mark S. Shaefer	2
3	Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States 2018 ·AIDS Research and Human Retroviruses ·Lisa Ross, Denise Shortino, Mark S. Shaefer	20
4	HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing 2014 ·PLoS ONE ·Lisa Ross, Joseph Horton, Samiul Hasan, James R. Brown, Daniel Murphy, Edwin DeJesus, (unknown), Anthony LaMarca, (unknown), Douglas Ward, (unknown), Mark S. Shaefer	4
5	Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1–Infected Patients With or Without Hepatitis B or C Coinfection 2012 ·HIV Clinical Trials ·(unknown), (unknown), (unknown), Mark S. Shaefer	6
6	Inflammatory Biomarker Changes and Their Correlation with Framingham Cardiovascular Risk and Lipid Changes in Antiretroviral-Naive HIV-Infected Patients Treated for 144 Weeks with Abacavir/Lamivudine/Atazanavir with or without Ritonavir in ARIES 2012 ·AIDS Research and Human Retroviruses ·Benjamin Young, Kathleen Squires, Lisa Ross, Lizette Santiago, Louis Sloan, Henry Zhao, (unknown), Gary E. Pakes, David A. Margolis, Mark S. Shaefer	17
7	A Study of HIV Provider Attitudes Toward HLA-B5701* Testing in the United States 2009 ·AIDS Patient Care and STDs ·Maria Watson, Lisa Patel, Belinda Ha, Paul Wannamaker, Robert L. Cuffe, Mark S. Shaefer	3
8	First large, multicenter, open-label study utilizing HLA-B5701 screening for abacavir hypersensitivity in North America 2008 ·AIDS* ·Benjamin Young, Kathleen Squires, Parul Patel, Edwin DeJesus, Nicholaos Bellos, Daniel Berger, Denise Sutherland‐Phillips, Qiming Liao, Mark S. Shaefer, Paul Wannamaker	62
9	High sensitivity of HLA-B5701 in Whites and Blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR) 2007 ·Murdoch Research Repository (Murdoch University)* ·Michael S. Saag, Ramani Balu, Philip S. Brachman, Britt Stancil, Michael Mosteller, Paul Wannamaker, Denise Sutherland‐Phillips, Emma Jane Phillips, S. Mallal, Mark S. Shaefer	8
10	The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial 2006 ·The Lancet ·Joseph J. Eron, Patrick Yéni, Joseph Gathe, Vicente Estrada, Edwin DeJesus, Schlomo Staszewski, Philip Lackey, Christine Katlama, Benjamin Young, Linda Yau, Denise Sutherland‐Phillips, Paul Wannamaker, Cindy Vavro, Lisa Patel, (unknown), Mark S. Shaefer	258
11	Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection 2006 ·HIV Clinical Trials ·Peter Ruane, (unknown), Edwin DeJesus, Daniel S Berger, Robin Dretler, Allan Rodríguez, Douglas Ward, Michael L. Lim, Qiming Liao, (unknown), Marty St. Clair, (unknown), Mark S. Shaefer	8
12	Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects 2005 ·The Journal of Infectious Diseases ·Joel E. Gallant, Allan Rodríguez, Winkler G. Weinberg, Benjamin Young, Daniel S Berger, Michael L. Lim, Qiming Liao, Lisa Ross, Judy Johnson, Mark S. Shaefer, (unknown)	109
13	Twice‐Daily Trizivir versus Combivir‐Abacavir in Antiretroviral‐Experienced Adults with Human Immunodeficiency Virus‐1 Infection: A Formulation‐Switch Trial 2003 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Margaret A. Fischl, (unknown), Charles Farthing, Melanie Thompson, Nicholaos Bellos, Vanessa C. Williams, Teresa L. Kauf, Paul Wannamaker, Mark S. Shaefer	1
14	Genotypic and Phenotypic Cross-Resistance Patterns to Lopinavir and Amprenavir in Protease Inhibitor-Experienced Patients with HIV Viremia 2002 ·AIDS Research and Human Retroviruses ·(unknown), Qiming Liao, Gregory Fusco, Marty St. Clair, Mark S. Shaefer, Lisa Ross	21
15	Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection 2000 ·AIDS ·Joseph J. Eron, (unknown), Peter Ruane, Stephen Becker, (unknown), Robin L. Fisher, Jerry M. Tolson, Mark S. Shaefer	49
16	SUCCESSFUL PROPHYLAXIS OF CYTOMEGALOVIRUS DISEASE AFTER PRIMARY CMV EXPOSURE IN LIVER TRANSPLANT RECIPIENTS 1991 ·Transplantation ·Robert J. Stratta, Mark S. Shaefer, (unknown), Rodney S. Markin, Robert Wood, Alan N. Langnas, Elizabeth Reed, Gail L. Woods, Jeremiah P. Donovan, T Pillen, Shujun Li, (unknown), Byers W. Shaw	42
17	Sensory/Mixability Preference Evaluation of Cholestyramine Powder Formulations 1990 ·DICP ·Mark S. Shaefer, Paul W. Jungnickel, (unknown), Norman R. Marquis, (unknown)	3
18	Drug-Induced Hypertrichosis: Case Report and Review of the Literature 1990 ·DICP ·(unknown), Mark S. Shaefer, Robert J. Stratta, (unknown), (unknown), Byers W. Shaw	10
19	HYDRALAZINE-INDUCED CHOLESTATIC JAUNDICE FOLLOWING LIVER TRANSPLANTATION 1989 ·Transplantation ·Mark S. Shaefer, (unknown), Robert Wood, (unknown)	4
20	Idiopathic Thromboembolism Associated with Triphasic Oral Contraceptives 1989 ·DICP ·(unknown), (unknown), Mark S. Shaefer, Stephen C. Raynor	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact